Download Content

The S-TIR™ Technology Platform: Vaccines Based On Conserved Immuno Mechanisms For Allergy & Cancer

Please enter your details into the form below to access the Webinar on ‘The S-TIR™ Technology Platform: Vaccines Based On Conserved Immuno Mechanisms For Allergy & Cancer‘. Hosted by Geert Mudde, Founder, Chief Scientific Officer & Managing Director at S-TARget therapeutic GmbH/ OncoQR ML GmbH/ TYG oncology Ltd.

Contact Form

Submit your details to register your interest & to be kept up to date about relevant events. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.